GM Discloses $40,000 Lobbying Expenditures in Q1 2025

General Motors Company has recently reported $40,000 in lobbying expenses from the first quarter of 2025. This disclosure comes from a filing under the Lobbying Disclosure Act.

Focus Areas for GM’s Lobbying Efforts

The company’s lobbying efforts targeted several significant areas, including:

• Issues related to autonomous and electric vehicles – no specific legislation identified.
• Issues concerning AV legislation – no specific legislation identified.
• Concerns regarding cybersecurity and privacy – no specific legislation identified.

For more information on corporate lobbying, visit Quiver Quantitative.

Congressional Trading of GM Stock

In the past six months, members of Congress have traded GM stock once, with no purchases and one sale recorded.

Here’s a summary of Congressional trading activity involving GM stock:

To monitor congressional stock trading, check out Quiver Quantitative’s trading dashboard.

GM Insider Trading Activity

Insiders at GM have engaged in 13 open market trades over the past six months, including one purchase and twelve sales.

The following details the recent insider trades of GM stock:

• MARY T. BARRA (Chair & CEO) has made 0 purchases and 3 sales, selling 713,648 shares for approximately $38,942,692.
• CRAIG B. GLIDDEN (Executive Vice President & GC) has made 0 purchases and 5 sales, selling 383,142 shares for around $21,696,752.
• MARK L. REUSS (President) sold 122,283 shares for roughly $6,745,130.
• RORY HARVEY (Executive Vice President) has made 0 purchases and 3 sales, selling 18,226 shares for about $1,037,900.
• ALFRED F. JR. KELLY purchased 12,000 shares for an estimated $607,920.

To follow insider transactions, visit Quiver Quantitative’s insider trading dashboard.

GM Hedge Fund Investment Movements

Recently, 561 institutional investors have added shares of GM stock to their portfolios, while 616 have reduced their holdings in the most recent quarter.

Below are some noteworthy adjustments from major investors:

• CAPITAL WORLD INVESTORS offloaded 22,218,452 shares (-46.0%) in Q4 2024, valued at approximately $1,183,576,938.
• ARROWSTREET CAPITAL, LIMITED PARTNERSHIP sold 8,347,526 shares (-27.7%) in Q4 2024, valued at about $444,672,710.
• CAPITAL INTERNATIONAL INVESTORS cut 7,196,697 shares (-71.7%) in Q4 2024, valued at around $383,368,049.
• HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC decreased their holdings by 6,366,002 shares (-36.8%) in Q4 2024, worth approximately $339,116,926.
• BLACKROCK, INC. sold 6,009,772 shares (-5.7%) in Q4 2024, valued at about $320,140,554.
• BARCLAYS PLC removed 5,419,215 shares (-70.0%) in Q4 2024, valued at around $288,681,583.
• FMR LLC reduced their portfolio by 4,217,131 shares (-21.9%) in Q4 2024, valued at approximately $224,646,568.

To keep track of hedge funds’ stock portfolios, visit Quiver Quantitative’s institutional holdings dashboard.

GM’s Analyst Ratings Overview

In recent months, Wall Street analysts have penned reports on GM, with 4 firms issuing buy ratings and 4 firms offering sell ratings.

Here are some recent analyst ratings:

• Barclays assigned a “Negative” rating on 04/15/2025.
• Bernstein issued an “Underperform” rating on 04/07/2025.
• Cowen & Co. recommended a “Buy” rating on 03/06/2025.
• UBS gave a “Buy” rating on 02/03/2025.
• Wells Fargo assigned an “Underweight” rating on 02/03/2025.
• Evercore ISI recommended “Outperform” on 12/13/2024.
• Bank of America Securities issued a “Buy” rating on 12/04/2024.

To explore analyst ratings and price targets for GM, access Quiver Quantitative’s $GM forecast page.

Recent Price Targets for GM

Analysts have recently set various price targets for GM, with a median target of $60.0 over the past six months.

Here are some of the latest price targets:

• Philippe Houchois from Jefferies has a target price of $52.0 as of 10/30/2024.
• Daniel Ives from Wedbush set a target price of $60.0 on 10/23/2024.
• Dan Levy from Barclays established a target price of $70.0 on 10/23/2024.

This article is not financial advice. For further information, see Quiver Quantitative’s disclaimers.

The views and opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.